Clinical Trials Logo

Neuromuscular Block, Residual clinical trials

View clinical trials related to Neuromuscular Block, Residual.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05053594 Not yet recruiting - Clinical trials for Neuromuscular Blockade

Different Doses of Neostigmine for Reversal of Moderate Neuromuscular Blockade in Children

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

There is no recent information on the required dose of neostigmine for the reversal of cisatracurium-induced moderate neuromuscular blockade (NMB) [Train-of-four (TOF) count = 1-3)] in children. The aim of this study will be to evaluate by means of a prospective, randomized and double-blinded clinical trial, the time required for reversal of moderate NMB (TOFc 3) to T4/T1 (TOF ratio, TOFr) > 0.9 and TOFr = 1.0 after administration of different doses of neostigmine (10, 20 or 30 mcg/kg) or placebo in children undergoing inhalational (sevoflurane) general anesthesia. In addition, the probability of NMB reversal in less than 10 minutes, the presence of bradycardia, respiratory complications and postoperative vomiting will be evaluated. The time for reversal is expected to be inversely proportional to the administered dose of neostigmine.